Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the differential biological effects of a novel HDAC inhibitor [belinostat (PXD101)], in a wide panel of androgen-sensi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of oncology 2012-03, Vol.40 (3), p.711-720
Hauptverfasser:	LUCA GRAVINA, Giovanni, MARAMPON, Francesco, GIUSTI, Ilaria, CAROSA, Eleonora, DI SANTE, Stefania, RICEVUTO, Enrico, DOLO, Vincenza, TOMBOLINI, Vincenzo, JANNINI, Emmanuele A, FESTUCCIA, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylation - drug effects Androgens - metabolism Animals Apoptosis - drug effects Biological and medical sciences Cell Cycle Checkpoints - drug effects Cell Division - drug effects Cell Line Cell Line, Tumor Cell Proliferation - drug effects Epithelial Cells - drug effects Epithelial Cells - metabolism G2 Phase - drug effects Gene Expression Regulation, Neoplastic - drug effects Histone Deacetylase Inhibitors - pharmacology Histones - metabolism Humans Hydroxamic Acids - pharmacology Male Medical sciences Mice Mice, Nude Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - metabolism Nephrology. Urinary tract diseases Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Receptors, Androgen - metabolism Sulfonamides Transfection - methods Tumors Tumors of the urinary system Urinary tract. Prostate gland Xenograft Model Antitumor Assays - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!